A fundamental question for placebo research is whether such responses are a predisposition, quantifiable by brain characteristics. We examine this issue in chronic back pain (CBP) patients who participated in a double-blind brain imaging (functional magnetic resonance imaging) clinical trial. We recently reported that when the 30 CBP participants were treated, for 2 weeks, with topical analgesic or no drug patches, pain and brain activity decreased independently of treatment type and thus were attributed to placebo responses. Here we examine in the same group brain markers for predicting placebo responses-that is, for differentiating between posttreatment persistent CBP (CBPp) and decreasing CBP (CBPd) groups. At baseline, pain and brain activity for rating spontaneous fluctuations of back pain were not different between the 2 groups. However, on the basis of brain activity differences after treatment, we identified that at baseline the extent of information shared (functional connectivity) between left medial prefrontal cortex and bilateral insula accurately (0.8) predicted posttreatment groups. This was validated in an independent cohort. Additionally, by means of frequency domain contrasts, we observe that at baseline, left dorsolateral prefrontal cortex high-frequency oscillations also predicted treatment outcomes and identified an additional set of functional connections distinguishing treatment outcomes. Combining medial and lateral prefrontal functional connections, we observe a statistically higher accuracy (0.9) for predicting posttreatment groups. These findings indicate that placebo response can be identified a priori at least in CBP, and that neuronal population interactions between prefrontal cognitive and pain processing regions predetermine the probability of placebo response in the clinical setting. Ó
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Introduction
Placebo conditioning studies demonstrate that placebo analgesia is a true antinociceptive effect with psychobiological origins [16, 42, 43] . However, further investigations into mechanisms that induce placebo analgesia in chronic pain are warranted to potentially improve treatment strategies and also to be able to design more effective clinical trials.
In a recent placebo-controlled, double-blind, clinical trial for 5% lidocaine topical patch treatment, we reported that the active treatment was not significantly different from placebo in its effectiveness for treating chronic back pain (CBP) [24] . A thorough examination of the data, corroborated by several reports in the literature [13, 24, 28, 29, 35, 49] , demonstrated that 5% lidocaine relieves pain through a placebo effect. We also confirmed that the overall decrease in clinical pain was due to the use of the patch or treatment and not a consequence of spontaneous remission in chronic pain because an untreated CBP group (observation-only control) demonstrated minimal change in back pain. The placebo patch treatment was effective in nearly half of the patients (independent of the type of treatment), while the remaining patients demonstrated little or no change in back pain [24] . To investigate the mechanisms for this marked interindividual variability in pain relief with a placebo treatment, here we investigate brain functional connectivity differences between the 2 groups at baseline, testing the hypothesis that in CBP patients placebo responses are contingent on predispositions that may be captured with brain network properties.
